SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.
December 12, 2022
As of 16 May 2022, a total of 73 pts received SEA-BCMA. Patient baseline characteristics are summarized in Table 1.
The most common non-hematologic, treatment-emergent adverse events (TEAEs) in Parts B (n=15), C1 (n=12), and C2 (n=8) were fatigue (33%, 50%, and 25%), back pain (20%, 17%, and 25%), pneumonia (7%, 25%, and 25%), and cough (20%, 8%, and 25%). The most common hematologic TEAE was anemia (42% in Part C1). The most common ≥Grade 3 TEAEs were anemia (33% in Part C1) and pneumonia (7%, 25%, and 0% for Parts B, C1, and C2, respectively).
Both intensive SEA-BCMA dosing (Part B) and the addition of DEX (Part C1) showed increased ORRs relative to Q2W monotherapy (Part A; Table 2). In Part B (n=15), the ORR was 27% (95% CI: 7.8, 55.1); median duration of response (DOR) was 6.5 months (95% CI: 1.8, -); 3 pts remain on treatment, including 2 responders. In Part C1 (n=12), the ORR was 17% (95% CI: 2.1, 48.4); the median DOR was not yet reached; 1 responding pt remains on treatment.
For the combination of the intensive SEA-BCMA dosing schedule and the addition of DEX (Part C2), the ORR across both SEA-BCMA dose levels (800 mg [n=3] and 1600 mg [n=5]) was 38% (n=8; 95% CI: 8.5, 75.5); median DOR was not yet reached; 2 responding pts remain on treatment.
The combined ORRs of both intensive dosing cohorts (Parts B + C2) relative to both standard dosing (Q2W) cohorts (Parts A [1600 mg SEA-BCMA] + C1) were 30% versus 15%, respectively (Table 2).
There are no resources, links or videos to display for this treatment.